97 related articles for article (PubMed ID: 6103646)
1. Further evidence for the existence of multiple receptors for dopamine in the central nervous system.
Iversen LL; Quik M; Emson PC; Dowling JE; Watling KJ
Adv Biochem Psychopharmacol; 1980; 21():193-202. PubMed ID: 6103646
[No Abstract] [Full Text] [Related]
2. Central nervous system dopamine receptors.
Creese I
Adv Biochem Psychopharmacol; 1980; 21():235-42. PubMed ID: 6103649
[No Abstract] [Full Text] [Related]
3. Detection of multiple receptors for dopamine.
Spano PF; Memo M; Stefanini E; Fresia P; Trabucchi M
Adv Biochem Psychopharmacol; 1980; 21():243-51. PubMed ID: 7376971
[No Abstract] [Full Text] [Related]
4. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
Marshall AM; Mishra RK
Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
[No Abstract] [Full Text] [Related]
5. [Effect of psychotropic drugs on the central dopamine metabolism (example: neuroleptics)].
Havemann U
Arzneimittelforschung; 1981; Suppl 27():18-22. PubMed ID: 6118158
[No Abstract] [Full Text] [Related]
6. Clinical evidence for multiple dopamine receptors in man.
Meltzer HY
Commun Psychopharmacol; 1979; 3(6):457-70. PubMed ID: 44694
[No Abstract] [Full Text] [Related]
7. [Problem of neuronal reception and the dopamine hypothesis of schizophrenia].
Lideman RR; Zlobina GP; Mukhin AG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):762-9. PubMed ID: 6106337
[No Abstract] [Full Text] [Related]
8. Multiple forms of the D1 dopamine receptor: its linkage to adenylate cyclase and psychopharmacological effects.
Mailman RB; Schulz DW; Kilts CD; Lewis MH; Rollema H; Wyrick S
Psychopharmacol Bull; 1986; 22(3):593-8. PubMed ID: 2879302
[No Abstract] [Full Text] [Related]
9. Radioligand binding studies: evidence for multiple dopamine receptors.
Creese I; Sibley DR
Commun Psychopharmacol; 1979; 3(6):385-95. PubMed ID: 546587
[No Abstract] [Full Text] [Related]
10. Site-specific blockade of dopamine receptors by neuroleptic agents in human brain.
Borison RL; Fields JZ; Diamond BI
Neuropharmacology; 1981 Dec; 20(12B):1321-2. PubMed ID: 6119643
[No Abstract] [Full Text] [Related]
11. Dopamine-sensitive adenylate cyclase and receptor binding activities after acute and chronic neuroleptic drug treatment.
Clement-Cormier Y
Adv Biochem Psychopharmacol; 1980; 24():103-11. PubMed ID: 6105768
[No Abstract] [Full Text] [Related]
12. [Action of etmozin and ethacizin on dopaminergic adenylate cyclase of the striate system of the brain].
Baldenkov GN; Ratner EI; Rozenshtraukh LV; Tkachuk VA
Biull Eksp Biol Med; 1984 Oct; 98(10):448-50. PubMed ID: 6149776
[TBL] [Abstract][Full Text] [Related]
13. [Dependence of the antipsychotic effect of neuroleptics on their dopamine-blocking properties].
Arushanian EB
Farmakol Toksikol; 1982; 45(5):118-26. PubMed ID: 6128251
[No Abstract] [Full Text] [Related]
14. No evidence for increased dopamine receptor binding in superresponsive mice after a single dose of neuroleptics.
Hyttel J
Adv Biochem Psychopharmacol; 1980; 24():167-73. PubMed ID: 6105773
[No Abstract] [Full Text] [Related]
15. Classification of dopamine receptors.
Creese I; Sibley DR; Leff S
Adv Biochem Psychopharmacol; 1983; 37():255-66. PubMed ID: 6416028
[No Abstract] [Full Text] [Related]
16. Localization of dopamine receptors in rat brain.
Reisine TD; Nagy JI; Fibiger HC; Yamamura HI
Brain Res; 1979 Jun; 169(1):209-14. PubMed ID: 455093
[No Abstract] [Full Text] [Related]
17. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties and localization of dopamine-sensitive adenylate cyclase in the carp retina.
Van Buskirk R; Watling KJ
Fed Proc; 1984 Sep; 43(12):2719-24. PubMed ID: 6205901
[TBL] [Abstract][Full Text] [Related]
19. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
[TBL] [Abstract][Full Text] [Related]
20. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system.
Spano PF; Govoni S; Trabucchi M
Adv Biochem Psychopharmacol; 1978; 19():155-65. PubMed ID: 358777
[No Abstract] [Full Text] [Related]
[Next] [New Search]
